Total buying$00 buys
MIRM
Mirum Pharmaceuticals, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$00 sells
Net open-market+$0Buying minus selling
Active insiders2Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 14, 2026
Open-market transaction mix · 0 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 0 | 2 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (2)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- PC+$211.2k
- MP+$0
MIRM transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
MIRMMirum Pharmaceuticals, Inc. | Myers Robert PaulCMO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
MIRMMirum Pharmaceuticals, Inc. | Myers Robert PaulCMO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
MIRMMirum Pharmaceuticals, Inc. | Peetz ChristopherCEO | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
MIRMMirum Pharmaceuticals, Inc. | Peetz ChristopherCEO | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
MIRMMirum Pharmaceuticals, Inc. | Peetz ChristopherCEO | M · exerciseSEC filing ↗ | $109kView disclosure → | |
MIRMMirum Pharmaceuticals, Inc. | Peetz ChristopherCEO | M · exerciseSEC filing ↗ | $101kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period6transactionstxns
- M · Option exercise · dominant4 · 67%
- A · Grants / awards2 · 33%
Activity by reported role
A joint filing can contribute to multiple rolesChief executive officer4
CMO2
Reported Holdings After
Separated by insider, security, and ownership type
Peetz ChristopherCommon Stock · Direct
206,637Oct 06, 2026
Peetz ChristopherEmployee Stock Option (right to buy) · Direct
233,108Oct 06, 2026
Myers Robert PaulEmployee Stock Option (right to buy) · Direct
40,000Oct 09, 2026
Myers Robert PaulRestricted Stock Units · Direct
25,000Oct 09, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Mirum Pharmaceuticals, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Mirum Pharmaceuticals, Inc.?
Myers Robert Paul, Peetz Christopher.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.